2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15211
    MRK 003 623165-93-5 98%
    MRK 003 is a potent, selective and orally active γ-secretase inhibitor. MRK 003 reduce brain Aβ production in vivo. MRK 003 induces caspase-dependent apoptosis and inhibits tumor cell proliferation in vivo and in vitro.
    MRK 003
  • HY-15376
    Besipirdine 119257-34-0 98%
    Besipirdine is a non-receptor-dependent cholinomimetic agent with noradrenergic activity. Besipirdine inhibits voltage-dependent sodium and potassium channels.
    Besipirdine
  • HY-15500
    JM6 1008119-83-2 98%
    JM6 is a weak kynurenine 3-monooxygenase (KMO) inhibitor with an IC50 of 19.85 μM for mouse KMO. JM6 can be used for Alzheimer's diseases research.
    JM6
  • HY-15502
    PF-3635659 931409-24-4 98%
    PF-3635659 is a potent antagonist of the muscarinic M3 receptor (mAChR3). PF-3635659 can be used for chronic obstructive pulmonary disease (COPD) research.
    PF-3635659
  • HY-15522
    WAY-267464 847375-16-0 98%
    WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder.
    WAY-267464
  • HY-15786
    SGE-201 35882-85-0 98%
    SGE-201 is an allosteric modulator of N-methyl-D-aspartate receptors (NMDARs), demonstrating significant neuroprotective effects by enhancing NMDAR-mediated responses while differing in action among various blockers in neuronal networks.
    SGE-201
  • HY-15977
    (S)-P7C3-OMe 1235481-43-2 98%
    (S)-P7C3-OMe, P7C3-A20 hydroxylated analog, is the (S)-enantiomer of P7C3-OMe. P7C3-OMe is a pro-neurogenic compound, can be used for the research of neuropsychiatric and/or neurodegenerative disease.
    (S)-P7C3-OMe
  • HY-16094
    Bethanidine sulfate 114-85-2 98%
    Bethanidine sulfate and its ortho-chloro derivative (BW 392C60) are potent adrenergic neurone blockers with sympathomimetic effects similar to bretylium and guanethidine in various animal models, particularly in cats. They inhibit the release of noradrenaline during nerve stimulation and enhance smooth muscle responses to adrenaline and noradrenaline. Bethanidine sulfate increases pressor responses to tyramine, though this effect diminishes with higher doses. Unlike guanethidine, Bethanidine sulfate does not deplete pressor amine content in the iris of cats post-administration. It also briefly inhibits autonomic cholinergic mechanisms and causes temporary neuromuscular paralysis in large doses, contrasting with its prolonged adrenergic neurone blocking effects.
    Bethanidine sulfate
  • HY-16170
    Desvenlafaxine succinate 448904-47-0 98%
    Desvenlafaxine succinate, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine succinate (DVS) shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter.
    Desvenlafaxine succinate
  • HY-16183
    Echothiopate iodide 513-10-0 98%
    Echothiopate iodide is a potent hBChE (human butyrylcholinesterase) inhibitor. Echothiopate iodide is a long-acting anticholinesterase agent. Echothiopate iodide can be used for glaucoma research.
    Echothiopate iodide
  • HY-16252
    Hexafluorenium dibromide 317-52-2 98%
    Hexafluorenium dibromide (Mylaxen) is a potent cholinesterase (ChE) inhibitor with pI50 value of 6.96 and Ki value of 2.4 nM for human plasma cholinesterase (ChE).
    Hexafluorenium dibromide
  • HY-16505
    Triclofos sodium 7246-20-0 98%
    Triclofos sodium is a drug used to suppress insomnia and for sedation and has sedative activity. Triclofos sodium is used in children for sedation during painless medical procedures, particularly in children with neurocognitive disorders. Triclofos sodium has similar physiological and pharmacological properties to chloral and therefore can be used as a substitute when necessary. The safety and efficacy of Triclofos sodium have been demonstrated in pediatric populations with high rates of neurocognitive disorders.
    Triclofos sodium
  • HY-16731
    Sembragiline 676479-06-4 98%
    Sembragiline (EVT 302) is a potent, selective and reversible monoamine oxidase B (MAO-B) inhibitor. Sembragiline reduces the metabolism of dopamine and other amine neurotransmitters by inhibiting the activity of the MAO-B enzyme, thereby potentially increasing the concentration of these neurotransmitters in the brain. Inhibition of the MAO-B enzyme also reduces the formation of toxic reactive oxygen species (ROS) that play a role in the pathological process of AD. Sembragiline has good oral activity and blood-brain barrier permeability. Sembragiline can be used in studies of AD, especially in patients with AD who show increased MAO-B activity.
    Sembragiline
  • HY-16736
    Centanafadine 924012-43-1 99.62%
    Centanafadine is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with IC50s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.
    Centanafadine
  • HY-16765
    Axelopran 949904-48-7 98%
    Axelopran (TD-1211) is an opioid receptor antagonist with pKi values of 9.8, 8.8 and 9.9 for human recombinant μ and δ receptors and guinea pig κ receptor, respectively.
    Axelopran
  • HY-16996
    BD-1047 138356-20-4 98%
    BD-1047 is a selective functional antagonist of sigma receptors. BD-1047 attenuates Apomorphine (HY-12723)-induced climbing and Phencyclidine-induced head twitches.
    BD-1047
  • HY-17018
    Napitane 148152-63-0 98%
    Napitane (A 75200) is a groundbreaking catecholamine uptake inhibitor that exhibits inhibitory effects on α-adrenergic receptors and shows promise for antidepressant activity in depression research.
    Napitane
  • HY-17032
    Indeloxazine 60929-23-9 98%
    Indeloxazine ((rac)-AS1069562 free base) is a brain active compound with anti-amnesic activity. Indeloxazine significantly prolonged the step latency in senescence accelerated mice (SAM-P/8/Ta), indicating that it has a promoting effect on brain function. Indeloxazine has a broader pharmacology than piracetam and exhibits stronger anti-amnesic activity. Indeloxazine has also been used as an anticonvulsant compound, further supporting its potential use in neuroprotection and behavioral improvement.
    Indeloxazine
  • HY-17487
    Miroprofen 55843-86-2 98%
    Miroprofen (Y 0213) is an orally active nonsteroidal anti-inflammatory analgesic (NSAID). Miroprofen exhibits anti-inflammatory, analgesic and anti-platelet activities.
    Miroprofen
  • HY-17495
    Carteolol 51781-06-7 98%
    Carteolol is a non-selective β-adrenoceptor antagonist. Carteolol induces apoptosis via a caspase activated and mitochondrial-dependent pathway. Carteolol can be used for glaucoma research.
    Carteolol
Cat. No. Product Name / Synonyms Application Reactivity